CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study Thursday, 12th December at 9:15 am •Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery •Factors supporting the go-ahead for the 212-person registration study in the target population include: ◦Multikine led to significant rates of tumor regression ◦Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit ◦Target population is likely to show significant survival prolongation in the confirmatory study •Confirmatory study target population selection is based on: ◦Strong statistical significance in a large subgroup of 114 patients ◦Subgroup analysis was pre-defined in the statistical analysis plan (SAP) ◦Strong biological rationale for the results based on Multikine's mechanism of action (MOA)
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more